ZA201708223B - Endostatin fragments and variants for use in treating fibrosis - Google Patents

Endostatin fragments and variants for use in treating fibrosis

Info

Publication number
ZA201708223B
ZA201708223B ZA2017/08223A ZA201708223A ZA201708223B ZA 201708223 B ZA201708223 B ZA 201708223B ZA 2017/08223 A ZA2017/08223 A ZA 2017/08223A ZA 201708223 A ZA201708223 A ZA 201708223A ZA 201708223 B ZA201708223 B ZA 201708223B
Authority
ZA
South Africa
Prior art keywords
variants
treating fibrosis
endostatin fragments
endostatin
fragments
Prior art date
Application number
ZA2017/08223A
Other languages
English (en)
Inventor
Carol Feghali¿Bostwick
Terence E Ryan
Hal S Padgett
Matthew Mcgee
Barry R Holtz
Original Assignee
Ibio Inc
Novici Biotech Llc
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ibio Inc, Novici Biotech Llc, Musc Found For Res Dev filed Critical Ibio Inc
Publication of ZA201708223B publication Critical patent/ZA201708223B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2017/08223A 2015-06-05 2017-12-04 Endostatin fragments and variants for use in treating fibrosis ZA201708223B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562171889P 2015-06-05 2015-06-05
US201562257607P 2015-11-19 2015-11-19
PCT/US2016/035858 WO2016197018A1 (en) 2015-06-05 2016-06-03 Endostatin fragments and variants for use in treating fibrosis

Publications (1)

Publication Number Publication Date
ZA201708223B true ZA201708223B (en) 2018-11-28

Family

ID=56236074

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/08223A ZA201708223B (en) 2015-06-05 2017-12-04 Endostatin fragments and variants for use in treating fibrosis

Country Status (10)

Country Link
US (2) US10844392B2 (enExample)
EP (1) EP3303383A1 (enExample)
JP (2) JP6952685B2 (enExample)
KR (1) KR20180033499A (enExample)
CN (2) CN107849117B (enExample)
AU (2) AU2016270428B2 (enExample)
BR (1) BR112017026209A2 (enExample)
CA (1) CA2988299C (enExample)
WO (1) WO2016197018A1 (enExample)
ZA (1) ZA201708223B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017026209A2 (pt) * 2015-06-05 2018-11-27 Ibio, Inc. fragmentos e variantes de endostatinas para uso no tratamento de fibrose
TW202348622A (zh) * 2018-09-14 2023-12-16 李蘭 史丹佛學院理事會 sPD-1變異體 – FC融合蛋白
US20210008173A1 (en) * 2019-07-10 2021-01-14 Musc Foundation For Research Development Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury
EP3996694A1 (en) * 2019-07-31 2022-05-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptides as inhibitors of fibrotic matrix accumulation
JP7493945B2 (ja) * 2020-01-28 2024-06-03 ポーラ化成工業株式会社 培養組織の観察方法、培養方法、評価方法及び培養器具
US20230265407A1 (en) * 2020-07-02 2023-08-24 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects
EP4251130A4 (en) * 2020-11-30 2024-12-11 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
EP4392056A4 (en) * 2021-09-07 2025-12-24 Musc Found For Res Dev Endostatin peptides for the treatment of tumors, fibrosis, and acute lung injury

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US750375A (en) 1904-01-26 Potato-digger
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5093258A (en) 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
HU215581B (hu) 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5756671A (en) 1994-06-02 1998-05-26 Mitotix, Inc. CDC37 cell-cycle regulatory protein, and uses related thereto
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DE19535939A1 (de) 1995-09-27 1997-04-03 Agfa Gevaert Ag Fotografisches Material
KR20010015868A (ko) 1997-12-08 2001-02-26 베쓰 이스라엘 디코니스 메디칼 센터 피치아 효모 발현계를 사용하여 항혈관형성 단백질인엔도스타틴, 안지오스타틴 또는 레스틴을 생성시키는 방법
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
KR20010052566A (ko) * 1998-06-03 2001-06-25 윌리엄 뉴 엔도스타틴 단백질을 포함하는 단백질 올리고머 조성물 및이의 사용방법
US6399075B1 (en) 1998-07-02 2002-06-04 President And Fellows Of Harvard College Compositions and methods for treating Papillomavirus-infected cells
CA2360670A1 (en) 1999-02-05 2000-08-10 Hilary Koprowski Production of biomedical peptides and proteins in plants using transcomplementation systems
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
WO2004070016A2 (en) 2003-02-03 2004-08-19 Fraunhofer Usa Inc. System for expression of genes in plants
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
US20110038865A1 (en) * 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
US8507441B2 (en) 2009-10-22 2013-08-13 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Use of endostatin peptides for the treatment of fibrosis
US20140057831A1 (en) * 2011-07-19 2014-02-27 Thrasos Innovation, Inc. Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
BR112017026209A2 (pt) 2015-06-05 2018-11-27 Ibio, Inc. fragmentos e variantes de endostatinas para uso no tratamento de fibrose

Also Published As

Publication number Publication date
WO2016197018A8 (en) 2017-07-13
AU2021200765B2 (en) 2023-04-13
JP7404320B2 (ja) 2023-12-25
JP2018524019A (ja) 2018-08-30
EP3303383A1 (en) 2018-04-11
AU2016270428B2 (en) 2020-11-26
JP2022002527A (ja) 2022-01-11
CN115925878A (zh) 2023-04-07
CA2988299A1 (en) 2016-12-08
WO2016197018A9 (en) 2017-01-19
JP6952685B2 (ja) 2021-10-20
US10844392B2 (en) 2020-11-24
WO2016197018A1 (en) 2016-12-08
CN107849117A (zh) 2018-03-27
CA2988299C (en) 2023-10-31
BR112017026209A2 (pt) 2018-11-27
AU2021200765A1 (en) 2021-03-04
US20180179263A1 (en) 2018-06-28
US20210108221A1 (en) 2021-04-15
CN107849117B (zh) 2022-08-26
KR20180033499A (ko) 2018-04-03
AU2016270428A1 (en) 2018-01-25
US11912755B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
IL278062B (en) Plasma kallikrein-binding proteins and their uses in the treatment of hereditary angioedema
ZA201708223B (en) Endostatin fragments and variants for use in treating fibrosis
IL259570A (en) Combined therapy and their uses and methods
GB201509086D0 (en) Process for removing chloropropanols and/or glycidol
IL236739B (en) Antenna formed from plates and methods useful in conjunction therewith
IL251759A0 (en) Preparations and methods for treating insomnia
GB201511382D0 (en) Novel compounds and their use in therapy
ZA202108602B (en) Anti-tnfalpha-antibodies and functional fragments thereof
SG11202000029PA (en) Anti-tnfalpha-antibodies and functional fragments thereof
IL257820A (en) Aminoglycosides for the treatment of genetic diseases
GB201621394D0 (en) Improvements in and relating to waste treatment
IL250980A0 (en) Mucolytic agents for use in the treatment of pulmonary sarcoidosis
IL247938A0 (en) Onconas for use in the treatment or prevention of viral infections
IL261261A (en) Antibodies against tnf-alpha and functional fragments thereof
IL261098A (en) Antibodies against tnf-alpha and functional fragments thereof
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
PL3406258T3 (pl) Lek do stosowania w leczeniu dny moczanowej
IL261793A (en) Anti-tnfalpha antibodies and their functional parts
GB201502983D0 (en) Composition and process
EP3271464A4 (en) Mirna mimetics and their use in treating sensory conditions
EP3110453A4 (en) Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
SG11201804140PA (en) Acidic-gas treating agent and acidic-gas treating method
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201511158D0 (en) Cell modification and application in therapy
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer